Skip Navigation

Cardiovascular Research 2005 67(4):678-688; doi:10.1016/j.cardiores.2005.04.029
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Dieterle, T.
Right arrow Articles by Dillmann, W. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dieterle, T.
Right arrow Articles by Dillmann, W. H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure

Thomas Dieterle1, Markus Meyer, Yusu Gu, Darrell D. Belke, Eric Swanson, Mitsuo Iwatate2, John Hollander, Kirk L. Peterson, John Ross, Jr. and Wolfgang H. Dillmann*

Department of Medicine, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0618, USA

* Corresponding author. Tel.: +1 858 534 3348; fax: +1 858 534 1626. Email address: wdillmann{at}uscd.edu

Background: Abnormalities of intracellular calcium handling are widely recognized as a common hallmark of heart failure in animal models and humans. Modifying the interaction of phospholamban (PLB) with the sarcoplasmic reticulum ATPase (SERCA) by PLB mutants improves cardiac function but may also lead to heart failure. In this study we describe the in vivo effects of a new approach to modify the PLB–SERCA interaction using a recombinant, intracellularly expressed chicken-antibody derived protein (PLADP) targeting the cytoplasmic domain of PLB in the cardiomyopathic BIO 14.6 hamster.

Methods and results: In vivo gene transfer was performed in 12–14-week-old BIO 14.6 cardiomyopathic hamsters using intracoronary delivery of adenovirus containing the PLADP or the β-galactosidase (LacZ) gene (8 x 109 PFU per animal). A third group was injected with saline (Sham). Echocardiography was performed before and, together with hemodynamic measurements, repeated 4–5 days after gene transfer. Indo-1 calcium transients and myocyte contractility were measured in isolated cardiomyocytes from the BIO 14.6 hamster transfected with the PLADP. Gene expression (LacZ) was found in 54 ± 15% of cells throughout the heart without any signs of myocardial inflammation. Echocardiographic and hemodynamic indices of left ventricular function were significantly increased after gene transfer with the PLADP, compared to controls. Measurements of myocyte contractility and calcium transients in isolated cardiac myocytes from BIO 14.6 hamsters revealed improved intracellular calcium handling and contractility.

Conclusion: In vivo adenoviral gene transfer with the PLADP resulted in short-term intracellular expression of a PLADP, improving LV function and enhancing myocardial contractility in the failing cardiomyopathic hamster heart. The PLADP enhanced contractility and cardiac function by improving intracellular calcium handling. Expression of antibody-derived protein represents a new approach to modify protein–protein interactions at the cellular level.

KEYWORDS Gene transfer; Phospholamban; SERCA; Phospholamban antibody; Cardiomyopathic hamster


1 Current address: University Hospital Basel, Division of Cardiology, Basel, Switzerland.

2 Current address: University of Yamaguchi, Division of Cardiology, Yamaguchi, Japan.

Time for primary review 25 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.